Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

ConclusionResults from this phase I study indicate that pimasertib has clinical activity in patients with locally advanced/metastatic melanoma, particularlyBRAF- andNRAS-mutated tumors, at clinically relevant doses associated with pERK inhibition in peripheral blood mononuclear cells.Trial RegistrationClinicalTrials.gov, NCT00982865
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research